Language:English
Language:

Xcessbio

Place your promotion here

You have no items in your shopping cart.

EPZ-5676 --- DOT1L inhibitor

Related Products

EPZ-5676 --- DOT1L inhibitor

$139.00
A highly potent and selective inhibitor of DOT1L methyltransferase with Ki of 70 pM, selectively blocking the binding of the cofactor, S-adenosylmethionine.
Catalog No. Unit Price Qty
M60123-2s 2mg solid $139.00
M60123-2 10 mM in DMSO (0.355 mL) $139.00

Details

Product Information
Molecular Weight: 562.71
Formula: C30H42N8O3
Purity: ≥ 98%
CAS#: 1380288-87-8
Solubility: DMSO up to 50 mM
Chemical Name: (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol
Storage: Powder: 4oC 1 year. DMSO: 4oC 3 month; -20oC 1 year.

Biological Activity:

EPZ-5676 is a highly potent and selective inhibitor of DOT1L methyltransferase with Ki of 70 pM, selectively blocking the binding of the cofactor, S-adenosylmethionine. It inhibits proliferation of MLL-AF4 rearranged cell line MV4-11 with an IC50 of 9 nM. It reduces H3K79 dimethylation with a cellular IC50 of 2.6 nM in MV4-11 cells. EPZ-5676 has over 10,000-fold selectivity against other HMTs. Its superior potency is associated with its increased enzyme residence time and prolonged cellular effects after washout. It can reduce H3K79 methylation in all cells, but only kill cells with MLL rearrangement, making it a good drug candidate for cancer therapy. Now EPZ-5676 is in phase I clinical trials for advanced hematologic malignancies, including acute Leukemia with rearrangement of the MLL gene. 

 

How to Use:

  • In vitro:  EPZ-5676 was used at 1 µM final concentration in vitro and in cellular assays.
  • In vivo:   Continuous intravenous infusion of EPZ-5676 at 70.5 mg/kg once per day for 21 days achieved complete tumor regressions in a nude rat subcutaneous xenograft model of MLL-rearranged leukemia.

 

Reference:

  1. 1. Robert A Copeland. Protein methyltransferases in cancer. (2013) AACR Annual Meeting.
  2. 2. Roy M Pollock. Preclinical Characterization of a Potent, Selective Inhibitor of the Protein Methyltransferase DOT1L for Use in the Treatment of MLL-Rearranged Leukemia. (2012) 54th ASH Annual Meeting and Exposition. 



Products are for research use only. Not for human use.

Description

Details

Product Information
Molecular Weight: 562.71
Formula: C30H42N8O3
Purity: ≥ 98%
CAS#: 1380288-87-8
Solubility: DMSO up to 50 mM
Chemical Name: (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol
Storage: Powder: 4oC 1 year. DMSO: 4oC 3 month; -20oC 1 year.

Biological Activity:

EPZ-5676 is a highly potent and selective inhibitor of DOT1L methyltransferase with Ki of 70 pM, selectively blocking the binding of the cofactor, S-adenosylmethionine. It inhibits proliferation of MLL-AF4 rearranged cell line MV4-11 with an IC50 of 9 nM. It reduces H3K79 dimethylation with a cellular IC50 of 2.6 nM in MV4-11 cells. EPZ-5676 has over 10,000-fold selectivity against other HMTs. Its superior potency is associated with its increased enzyme residence time and prolonged cellular effects after washout. It can reduce H3K79 methylation in all cells, but only kill cells with MLL rearrangement, making it a good drug candidate for cancer therapy. Now EPZ-5676 is in phase I clinical trials for advanced hematologic malignancies, including acute Leukemia with rearrangement of the MLL gene. 

 

How to Use:

  • In vitro:  EPZ-5676 was used at 1 µM final concentration in vitro and in cellular assays.
  • In vivo:   Continuous intravenous infusion of EPZ-5676 at 70.5 mg/kg once per day for 21 days achieved complete tumor regressions in a nude rat subcutaneous xenograft model of MLL-rearranged leukemia.

 

Reference:

  1. 1. Robert A Copeland. Protein methyltransferases in cancer. (2013) AACR Annual Meeting.
  2. 2. Roy M Pollock. Preclinical Characterization of a Potent, Selective Inhibitor of the Protein Methyltransferase DOT1L for Use in the Treatment of MLL-Rearranged Leukemia. (2012) 54th ASH Annual Meeting and Exposition. 



Products are for research use only. Not for human use.

Reviews

Write Your Review

How do you rate this product? *

Price:
Value:
Quality: